---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-062072"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:17:57.647741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alaunos reports Q4 2022 net loss $9.2M, cash $53M; TCR library expanded

## Summary
- Net loss $9.2M in Q4 2022 ($0.04/share) vs $11.8M ($0.05) prior year; full year loss $37.7M.
- Cash and restricted cash $53.0M; expects to fund operations into Q4 2023.
- Expanded TCR library with two new TCRs, doubling potential addressable market; improving patient match rate from 5% to 10%.
- Transitioned to cryopreserved cell product, reducing manufacturing time from 30 to 26 days (13% decrease).
- Phase 2 readiness targeted in 2023; interim data on multiple patients expected mid-2023.

## SEC filing metadata
- accession: 0001193125-23-062072
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/0001193125-23-062072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/d457628d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-062072
- JSON: https://secwatch.observer/filing/0001193125-23-062072.json
- Plain text: https://secwatch.observer/filing/0001193125-23-062072.txt

## Key facts
- Earnings Releases
  Alaunos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 7, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2022 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/0001193125-23-062072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.